Page last updated: 2024-10-30

leflunomide and Di Guglielmo Disease

leflunomide has been researched along with Di Guglielmo Disease in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Research Excerpts

ExcerptRelevanceReference
"Leflunomide is an immunomodulatory agent that has been approved for treatment of active RA."1.33Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents. ( Beneytout, JL; Leger, DY; Liagre, B, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Leger, DY1
Liagre, B1
Beneytout, JL1

Other Studies

1 other study available for leflunomide and Di Guglielmo Disease

ArticleYear
Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents.
    Apoptosis : an international journal on programmed cell death, 2006, Volume: 11, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Pr

2006